SynthesisScientific reports2025
Efficacy of single dose praziquantel against Schistosoma mansoni in East Africa: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Community-level prevalence and determinants of Schistosoma mansoni infection in river-crossing Kebeles of Mizan-Aman Town, Southwest Ethiopia, where mass drug administration targets only school-aged children.PLoS neglected tropical diseases · 2026Article
- Individual and spatial heterogeneity of praziquantel efficacy against Schistosoma mansoni within the context of repeated mass drug administration.Parasites & vectors · 2026Article
- Praziquantel efficacy and post-treatment reinfection and incidence of Schistosoma mansoni among school-aged children in Northern Uganda: a 24-week cohort study in a high transmission focus.BMC infectious diseases · 2026Article
- Nanostructured Lipid Carriers Enable In Vivo Efficacy of Parthenolide inPharmaceutics · 2026Article
- Stage specific immune responses to schistosomes may explain conflicting results in malaria-schistosome coinfection studies.Infectious Disease Modelling · 2025Article
- Structure-Activity Relationship and Target Investigation of Thiophen-2-yl-Pyrimidines againstbioRxiv : the preprint server for biology · 2025Article
- Photoaffinity labeling of protein targets in a complex metazoan: proof-of-concept using a probe forbioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Schistosoma causes a schistosomiasis which is one of the neglected tropical diseases that pose a major threat to public health in East Africa. Praziquantel (PZQ) is the first line drug to treat human schistosomiasis. However, there is scarcity of pooled and summarized data on PZQ efficacy to policymakers. Articles were searched from PubMed, Google Scholar, Web of Science, and Scopus databases. In total, 87 published articles were retrieved. Only studies conducted in English that reported the efficacy of PZQ against Schistosoma mansoni, regardless of the year, and studies with more than fifty positive cases were included in the present study. Excel software was used to extract the name of the authors, the total sample size, number of cured participants, the study area, and the year of publication. The pooled efficacy of PZQ against S. mansoni was analyzed using CMA Version 2.2 software. A total of 21 studies fulfilled the inclusion criteria for the present systematic review and meta-analysis. The overall pooled efficacy of PZQ was 85.0% (95% CI: 80.0-89.0%) against S. mansoni. In subgroup analysis, the efficacy of PZQ against S. mansoni was 90.4% in Ethiopia, 71.2% in Kenya, 97.9% in Rwanda, 75.4% in Tanzania, and 68.4% in Uganda. Its heterogeneity was high (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.